Value-based pricing for drugs theme and variations

JAMA - Journal of the American Medical Association

Volumn 319, Issue 21, 2018, Pages 2165-2166

  Kaltenboeck, Anna ^a   Bach, Peter B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACT; DRUG COST; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HUMAN; NOTE; VALUE-BASED INSURANCE DESIGN; ECONOMICS; FEE; HEALTH INSURANCE; PHARMACOECONOMICS; UNITED STATES;

GENERIC DRUG; PRESCRIPTION DRUG;

DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; INSURANCE, PHARMACEUTICAL SERVICES; PRESCRIPTION DRUGS; PRESCRIPTION FEES; UNITED STATES;

EID: 85048297531     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.4871     Document Type: Note

References (9)

1. Spark Therapeutics announces first-of-their-kind programs to improve patient access to LUXTURNA (voretigene neparvovec-rzyl), a one-time gene therapy treatment [press release]. Philadelphia, PA: Sparks Therapeutics. January 3, 2018.
2. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value: final evidence report. http://icer-review.org/wp-content/uploads/2017/06/MWCEPAC _VORETIGENE_FINAL_EVIDENCE_REPORT _02142018.docx.pdf. February 14, 2018. Accessed April 13, 2018.
3. Gottlieb S. Capturing the benefits of competition for patients: Presented at: the America’s Health Insurance Plans (AHIP) National Health Policy Conference; March 7, 2018; Washington, DC.
4. Generic Drug Access and Savings in the US. https://accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2 .pdf. Published 2017. Accessed April 13, 2018.
5. Bach PB, Pearson SD. Payer and policy maker steps to support value-based pricing for drugs. JAMA. 2015;314(23):2503-2504.
6. Silverman E. How a $37,000-a-year medicine sets a good model for drug pricing. STATNews. https://www.statnews.com/2017/04/03/regeneron-drug-price-model. Published April 3, 2017. Accessed April 14, 2018.
7. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16):1629-1630.
8. Mailankody S, Bach PB. Money-back guarantees for expensive drugs: wolf’s clothing but a sheep underneath [published online April 2, 2018]. Ann Intern Med. doi:10.7326/M18-0539
9. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.